<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta name="description" content="">
    <meta name="author" content="">

    <title>Viralchemy Inc</title>
    <link href="static/bootstrap/css/bootstrap.css" rel="stylesheet">
    <link href="static/fontawesome/css/font-awesome.min.css" rel="stylesheet">
    <link href="static/css/landing.css" type="text/css" rel="stylesheet">

    <!-- Custom Fonts -->
    <link href="https://fonts.googleapis.com/css?family=Lora:400,700,400italic,700italic" rel="stylesheet" type="text/css">
    <link href="https://fonts.googleapis.com/css?family=Montserrat:400,700" rel="stylesheet" type="text/css">


    <!-- HTML5 Shim and Respond.js IE8 support of HTML5 elements and media queries -->
    <!-- WARNING: Respond.js doesn't work if you view the page via file:// -->
    <!--[if lt IE 9]>
        <script src="https://oss.maxcdn.com/libs/html5shiv/3.7.0/html5shiv.js"></script>
        <script src="https://oss.maxcdn.com/libs/respond.js/1.4.2/respond.min.js"></script>
    <![endif]-->

</head>
<body id="page-top" data-spy="scroll" data-target=".navbar-fixed-top">
    <!-- Navigation -->
    <nav class="navbar navbar-custom navbar-fixed-top" role="navigation">
        <div class="container">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target=".navbar-main-collapse">
                    <i class="fa fa-bars"></i>
                </button>
                <a class="navbar-brand page-scroll" href="#page-top">Viralchemy</a>
            </div>

            <div class="collapse navbar-collapse navbar-right navbar-main-collapse">
                <ul class="nav navbar-nav">
                    <li class="hidden">
                        <a href="#page-top"></a>
                    </li>
                    <li>
                        <a class="page-scroll" href="#about">About</a>
                    </li>
                    <li>
                        <a class="page-scroll" href="#team">Team</a>
                    </li>
                    <li>
                        <a class="page-scroll" href="#opportunity">Opportunity</a>
                    </li>
                    <li>
                        <a class="page-scroll" href="#technology">Technology</a>
                    </li>
                    <li>
                        <a class="page-scroll" href="#contact">Contact</a>
                    </li>
                </ul>
            </div>
            <!-- /.navbar-collapse -->
        </div>
        <!-- /.container -->
    </nav>

    <!-- Intro Header -->
    <header class="intro" style='padding-top:0px'>
        <div class="intro-body">
            <div class="container">
                <div class="row">
                    <div class="intro-box col-md-10 col-md-offset-1">
                        <!-- h1 class="brand-heading" style='color:white !important;margin-bottom:6px'>Technically diverse. Unified motivation. Driven to do good.</h1 -->
                        <div class="intro-text">
                            Vi<sup>ralchemy</sup> is committed to improving human health through the
                            synergy of bioscience, creativity, and technology to innovate actionable
                            therapeutics for diseases of unmet need.
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <section id="about" class="content-section">
        <div class="container">
            <div class="row">
                <div class="col-md-12 ">
                    <h2>About</h2>
                    <p>
                        Vi<sup>ralchemy</sup> Inc. is a privately held, preclinical stage
                        biopharmaceutical company. Our goal is improving the health of all people
                        through the discovery and development of treatments for emerging viral diseases
                        neglected by the current pharmaceutical paradigm.
                    </p>
                </div>
            </div>
        </div>
    </section>

    <section id="team" class="container content-section">
        <div class="row">
            <div class="col-md-12">
                <h2>Team</h2>
                <h3>Management</h3>
                <div class="tagline">Technically diverse. Unified motivation. Innovative results</div>
                <div class="row management">
                    <div class="col-sm-6 col-md-2">
                        <div class="thumbnail">
                            <div class="caption">
                                <span class="name">Trevor V. Gale, Ph.D.</span><br />
                                Co-Founder <br />
                            </div>
                        </div>
                    </div>
                    <div class="col-sm-6 col-md-2">
                        <div class="thumbnail">
                            <div class="caption">
                                <span class="name">Timothy M. Horton, M.S.</span><br />
                                Co-Founder <br />
                            </div>
                        </div>
                    </div>
                    <div class="col-sm-6 col-md-2">
                        <div class="thumbnail">
                            <div class="caption">
                                <span class="name">Ben T. Bradley, M.D., Ph.D.</span><br />
                                Co-Founder <br />
                            </div>
                        </div>
                    </div>
                    <div class="col-sm-6 col-md-2">
                        <div class="thumbnail">
                            <div class="caption">
                                <span class="name">Andrew R. Hoffmann, B.S.</span><br />
                                Co-Founder <br />
                            </div>
                        </div>
                    </div>
                    <div class="col-sm-6 col-md-2">
                        <div class="thumbnail">
                            <div class="caption">
                                <span class="name">Ryan M. Hanson, MBA, M.S. </span><br />
                            </div>
                        </div>
                    </div>
                </div>
                <h3>Scientific Advisory</h3>
                <div class="row">
                    <div class="col-sm-6 col-md-3">
                        <div class="thumbnail">
                            <div class="caption">
                                <span class="name">Robert Garry, Ph.D.</span><br />
                                Professor, Tulane University School of Medicine<br />
                                Program Manager, Viral Hemorrhagic Fever Consortium<br />
                                Co-Founder, Zalgen Labs<br />
                            </div>
                        </div>
                    </div>
                    <div class="col-sm-6 col-md-3">
                        <div class="thumbnail">
                            <div class="caption">
                                <span class="name">William Wimley, Ph.D.</span><br />
                                Professor, Tulane University School of Medicine<br />
                            </div>
                        </div>
                    </div>
                </div>
                <h3>Strategic Advisory</h3>
                <div class="row">
                    <div class="col-sm-6 col-md-3">
                        <div class="thumbnail">
                            <div class="caption">
                                <span class="name">Tobin Dickerson, Ph.D.</span><br />
                                Professor, The Scripps Research Institute Department of Chemistry<br />
                                Co-Founder and Chief Scientific Officer, MiNDERA
                            </div>
                        </div>
                    </div>
                    <div class="col-sm-6 col-md-3">
                        <div class="thumbnail">
                            <div class="caption">
                                <span class="name">Ryan Boggs, CPA/ABV</span><br />
                                Ryan Boggs, CPA/ABV
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

    <section id="opportunity" class="content-section">
        <div class="container">
            <div class="row">
                <div class="col-md-12">
                    <h2>Opportunities...</h2>
                    <p>
                        Dengue virus has an enormous world-wide impact. Half of the global population resides in locales with dengue virus transmission. 
                    </p>
                    <p><iframe border="0" src="https://www.healthmap.org/dengue/en/" width="100%" height="500px"></iframe></p>
                    <p>
                        Annually, there are over 55 million cases of disease with 38 million
                        necessitating medical intervention and upwards of 20,000 deaths. In 2015, a
                        tetravalent vaccine was approved for community administration. Despite this
                        important first step towards disease control, there remains an unquestionable
                        need for a specific pharmaceutical treatment for dengue fever. Multiple
                        variables offer evidence for this need: the cautious vaccination approach
                        recommended by the World Health Organization, sustained economic burden of
                        dengue fever, and continued incidence of severe disease. While global mortality
                        from most communicable diseases decreased, dengue fever deaths increased 48%
                        over the last decade. Sadly those most likely to benefit from a specific
                        treatment are most often our most vulnerable population: pediatric patients.
                        Dengue has a disproportionately negative effect on children; the likelihood of
                        severe disease, hospitalization, and fatal outcome increases in pediatric
                        patients. Age notwithstanding, the average inpatient hospital stay for dengue
                        fever, dengue hemorrhagic fever, and dengue shock syndrome is ~5 days. While
                        hospitalization rates vary (~25% all symptomatic cases), one reality of the
                        cost of dengue is certain: of the global $8.9 billion annual economic burden,
                        hospitalization accounts for the highest direct cost. At Vi<sup>ralchemy</sup>
                        we recognize the human toll exacted by dengue virus and acknowledge both the
                        humanitarian and economic potential held by a pharmaceutical treatment that
                        alleviates this disease. We are developing such a treatment. 
                    </p>
                    <h3>...and Solutions</h3>
                    <p>
                        There is currently no approved treatment for dengue fever. As such, the current
                        standard of care involves non-specific, supportive therapy with careful fluid
                        management and pain control. This clinical approach addresses the symptom
                        without treating the cause of the disease. Vi<sup>ralchemy</sup>'s goal is to
                        address this gap in care by developing an antiviral therapy against dengue for
                        use by global healthcare providers. Ideally our therapy will be administered
                        immediately upon disease recognition/symptom onset in conjunction with a
                        molecular diagnostic. Our product acts directly on the virus at two distinct
                        stages of the replication cycle, halting disease progression and, consequently,
                        harboring potential to mitigate hospitalization of dengue fever patients.  
                    </p>
                </div>
            </div>
        </div>
    </section>

    <section id="technology" class="content-section">
        <div class="container">
            <div class="row">
                <div class="col-md-12">
                    <h2>Technology &amp; Pipeline</h2>
                    <p>
                        Viruses have two critical stages in their life cycle: infection and
                        replication. Infection encompasses the physical contact between, and entry of,
                        a virus and host cell. Replication features production of more virus within the
                        infected cell, carried out by host and viral machinery. Vi<sup>ralchemy</sup>'s
                        antiviral formulation addresses both stages of viral replication. Our lead
                        therapeutic candidate combines a small molecule and synthetic polypeptide; each
                        individual component possesses antiviral activity, though at distinct stages of
                        the viral replication cycle. The small molecule targets a host factor pertinent
                        to viral replication, leveraging the cell penetrating power of small molecules.
                        Vi<sup>ralchemy</sup>'s proprietary peptides—while not synonymous with
                        antibodies—sequester viral particles outside of cells, recapitulating
                        mechanistic properties of antibodies by abrogating subsequent infectivity. The
                        synergistic activity of the small molecule and polypeptide results in a robust
                        antiviral strategy exhibiting virtually no toxicity. Further, as an inherent
                        characteristic of targeting conserved factors, our broad-spectrum antiviral
                        agent (BSAA) products will offer rapid therapeutic portfolio expansion.
                    </p>
                    <img src="static/img/pipeline.png" alt="Pipeline graphic" />
                </div>
            </div>
        </div>
    </section>

    <section id="contact" class="content-section">
        <div class="container">
            <div class="row">
                <div class="col-md-12">
                    <div class="social pull-right">
                        <a href="https://twitter.com/viralchemyinc" target="_blank"><i class="fa fa-twitter-square fa-10" aria-hidden="true"></i></a>
                        <a href="https://www.linkedin.com/company/viruachemyinc" target="_blank"><i class="fa fa-linkedin-square fa-10" aria-hidden="true"></i></a>
                    </div>
                    <h2>Contact</h2>
                    <div class="address">
                        <!--
                        Address <br />
                        City, State Zip <br />
                        -->
                        <div class="email"><i class="fa fa-envelope-open fa-10" aria-hidden="true">&nbsp;</i><a href="mailto:info@viralchemy.com">info@viralchemy.com</a></div>
                    </div>
                </div>
            </div>
        </div>
    </section>

    <footer>
        <div class="container">
            <div class="copy">&copy; 2017 Viralchemy Inc. All rights reserved</div>
        </div>
    </footer>

    <!-- Footer -->
    <script src="static/js/jquery-1.11.0.min.js"></script>
    <script src="static/bootstrap/js/bootstrap.min.js"></script>
    <script src="static/js/jquery.easing.min.js"></script>
    <script src="static/js/script.js"></script>
    <script src="static/js/holder.min.js"></script>
    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-84215305-1', 'auto');
      ga('send', 'pageview');
    </script>
</body>
</html>
